RAMBA SINGH, A DELHI-BASED medical equipment distributor, is eagerly waiting to free up space in his warehouse, now occupied by over a dozen oxygen concentrators that he bought in March 2021 when India was reeling under the second wave of the Covid-19 pandemic. The Chinese concentrators, which Singh had bought from domestic companies for ₹25,000 each and rented out for at least ₹10,000 a day to Covid-19 patients, haven’t been used for over a year. “Since there is no demand, I offered these to small local hospitals at throwaway prices, but they didn’t want them,” says Singh, who plans to donate them to charity since he has already recovered their cost.
Ventilators, oxygen concentrators, personal protective equipment (PPE) kits, oxygen cylinders and many other items that were considered life-savers during the initial days of the pandemic are now gathering dust at hospitals and manufacturing units. These commanded premium prices when Covid-19 was at its peak, but with the infection curve seeing a downward trend after December 2021, these products are no longer in demand.
CHALLENGING TIMES
“These are very challenging times for manufacturers of Covid-19-critical medical devices who had invested in plants and production lines for FFP2 (N95-equivalent) masks, surgical masks, oxygen therapy (ventilators, oxygen concentrators, high nasal flow oxygen equipment), syringes, etc., as demand has ebbed sharply and manufacturers are left with huge capacities of plant and machinery and unsold inventories,” says Rajiv Nath, Forum Coordinator, Association of Indian Medical Device Industry (AiMeD).
This story is from the {{IssueName}} edition of {{MagazineName}}.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the {{IssueName}} edition of {{MagazineName}}.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber? Sign In
Look Before You Leap
In 2025, Investors Will Need To Factor In Volatility Across Asset Classes
"Focus on the challenge of each customer"
SHASHANK KUMAR MD & CO-FOUNDER I RAZORPAY Razorpay is India's first full-stack financial solutions company
PEDAL ON THE FUTURE
THE MG WINDSOR EV, WITH ITS FUTURISTIC AND MINIMALIST DESIGN, COMBINES THE BEST OF BOTH WORLDS-COMFORT AND TECHNOLOGY
BREATHE EASY
Whether you're battling allergies, looking to remove pollutants, or simply want to breathe easier, the right air purifier can make a difference
The Taste of India in a Glass
FROM ROYAL LIQUEURS TO DISTILLED MAHUA, INDIAN HERITAGE ALCOHOLIC BEVERAGES ARE HAVING THEIR DAY IN THE SUN
MISSING ADVISORS
INDIA HAS JUST ONE INVESTMENT ADVISOR FOR NEARLY EVERY 200,000 INVESTORS. AT A TIME WHEN RETAIL PARTICIPATION IN THE STOCK MARKETS IS BOOMING, THIS ASSUMES SIGNIFICANCE
TURNING A CORNER
SHARED ELECTRIC MOBILITY START-UP YULU'S SHIFT TO SERVICING THE QUICK COMMERCE SECTOR IS HELPING IT GROW FAST. IT IS NOW FOCUSSING ON IMPROVING ROAD SAFETY FEATURES AS IT TURNS EBITDA POSITIVE
REALITY CHECK
INDIAN STOCK MARKETS PLUNGED BEGINNING OCTOBER FOR A HOST OF REASONS, INCLUDING A FALL IN FII OWNERSHIP. HOW DEEP WILL THE CORRECTION BE?
TRUMP'S TRADE TANGO
The return of Donald Trump as the 47th President of the US has put the global economy on edge. India, too, is unlikely to remain unaffected. How will policymakers meet this latest challenge?
"The essence of the Trump administration will be transactional”
Global investor, analyst, and best-selling author Ruchir Sharma decodes why Donald Trump won the elections, what India should do, the risks, and more